BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 20371463)

  • 1. Elafin is a biomarker of graft-versus-host disease of the skin.
    Paczesny S; Braun TM; Levine JE; Hogan J; Crawford J; Coffing B; Olsen S; Choi SW; Wang H; Faca V; Pitteri S; Zhang Q; Chin A; Kitko C; Mineishi S; Yanik G; Peres E; Hanauer D; Wang Y; Reddy P; Hanash S; Ferrara JL
    Sci Transl Med; 2010 Jan; 2(13):13ra2. PubMed ID: 20371463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic and prognostic role of elafin in skin acute graft versus host disease: a systematic review.
    Bhattarai A; Shah S; Yadav R; Dhakal G; Neupane R; Paudel S; Bhandari P; Abu Serhan H; Sah R; Sah S; Barboza JJ
    Hematology; 2024 Dec; 29(1):2293497. PubMed ID: 38112182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited utility of plasma elafin as a biomarker for skin graft-versus-host disease following allogeneic stem cell transplantation.
    George L; Mahabal G; Mohanan E; Balasubramanian P; Peter D; Pulimood S; Lakshmi K; Jeyaseelan L; Abraham A; Srivastava A; Mathews V; George B
    Clin Exp Dermatol; 2021 Dec; 46(8):1482-1487. PubMed ID: 34081805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease.
    Zewde MG; Morales G; Gandhi I; Özbek U; Aguayo-Hiraldo P; Ayuk F; Baez J; Chanswangphuwana C; Choe H; DeFilipp Z; Etra A; Grupp S; Hexner EO; Hogan W; Javorniczky NR; Kasikis S; Kitko CL; Kowalyk S; Meedt E; Merli P; Nakamura R; Qayed M; Reshef R; Rösler W; Schechter T; Weber D; Wölfl M; Yanik G; Young R; Levine JE; Ferrara JLM; Chen YB
    Transplant Cell Ther; 2021 Dec; 27(12):988.e1-988.e7. PubMed ID: 34474163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elafin as a Predictive Biomarker of Acute Skin Graft-
    Solán L; Carbonell D; Muñiz P; Dorado N; Landete E; Chicano-Lavilla M; Anguita J; Gayoso J; Kwon M; Díez-Martín JL; Martínez-Laperche C; Buño I
    Front Immunol; 2021; 12():516078. PubMed ID: 33679728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of tissue elafin as an immunohistochemical marker for diagnosis of acute skin graft-versus-host disease: a pilot study.
    Mahabal GD; George L; Peter D; Bindra M; Thomas M; Srivastava A; Mathews V; George B; Pulimood SA
    Clin Exp Dermatol; 2019 Mar; 44(2):161-168. PubMed ID: 29882232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study.
    Levine JE; Logan BR; Wu J; Alousi AM; Bolaños-Meade J; Ferrara JL; Ho VT; Weisdorf DJ; Paczesny S
    Blood; 2012 Apr; 119(16):3854-60. PubMed ID: 22383800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease.
    Ferrara JL; Harris AC; Greenson JK; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Huber E; Landfried K; Akashi K; Vander Lugt M; Reddy P; Chin A; Zhang Q; Hanash S; Paczesny S
    Blood; 2011 Dec; 118(25):6702-8. PubMed ID: 21979939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A preliminary study on clinical diagnostic value of plasma elafin in skin acute graft-versus-host disease].
    Luo CW; Weng JY; Wu SJ; Lu ZS; Guo R; Du X
    Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):922-5. PubMed ID: 23363749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal elafin expression is an indicator of poor prognosis in cutaneous graft-versus-host disease.
    Brüggen MC; Petzelbauer P; Greinix H; Contassot E; Jankovic D; French L; Socié G; Rabitsch W; Kuzmina Z; Kalhs P; Knobler R; Stingl G; Stary G
    J Invest Dermatol; 2015 Apr; 135(4):999-1006. PubMed ID: 25405322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
    Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
    Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary elafin and kidney injury in hematopoietic cell transplant recipients.
    Hingorani S; Finn LS; Pao E; Lawler R; Schoch G; McDonald GB; Najafian B; Sandmaier B; Gooley T
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):12-20. PubMed ID: 25388519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High throughput sequential ELISA for validation of biomarkers of acute graft-versus-host disease.
    Fiema B; Harris AC; Gomez A; Pongtornpipat P; Lamiman K; Vander Lugt MT; Paczesny S
    J Vis Exp; 2012 Oct; (68):. PubMed ID: 23149907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarkers for acute GVHD: can we predict the unpredictable?
    Chen YB; Cutler CS
    Bone Marrow Transplant; 2013 Jun; 48(6):755-60. PubMed ID: 22863728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of CD4(+)CD25(hi)FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute graft-versus-host-disease.
    Magenau JM; Qin X; Tawara I; Rogers CE; Kitko C; Schlough M; Bickley D; Braun TM; Jang PS; Lowler KP; Jones DM; Choi SW; Reddy P; Mineishi S; Levine JE; Ferrara JL; Paczesny S
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):907-14. PubMed ID: 20302964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of ST2 With Organ-Specific Biomarker is More Sensitive and Specific for the Diagnosis of Acute Graft-vs-Host Disease.
    Wang B; Yin Y; Li Y; Liang Z; Liu W; Sun Y; Dong Y; Ren H
    Transplant Proc; 2023 Sep; 55(7):1706-1714. PubMed ID: 37385841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
    Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
    Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma biomarkers of lower gastrointestinal and liver acute GVHD.
    Harris AC; Ferrara JL; Braun TM; Holler E; Teshima T; Levine JE; Choi SW; Landfried K; Akashi K; Vander Lugt M; Couriel DR; Reddy P; Paczesny S
    Blood; 2012 Mar; 119(12):2960-3. PubMed ID: 22286196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pentraxin 3 plasma levels at graft-versus-host disease onset predict disease severity and response to therapy in children given haematopoietic stem cell transplantation.
    Dander E; De Lorenzo P; Bottazzi B; Quarello P; Vinci P; Balduzzi A; Masciocchi F; Bonanomi S; Cappuzzello C; Prunotto G; Pavan F; Pasqualini F; Sironi M; Cuccovillo I; Leone R; Salvatori G; Parma M; Terruzzi E; Pagni F; Locatelli F; Mantovani A; Fagioli F; Biondi A; Garlanda C; Valsecchi MG; Rovelli A; D'Amico G
    Oncotarget; 2016 Dec; 7(50):82123-82138. PubMed ID: 27893415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical, laboratory, and histopathologic indicators of the development of progressive acute graft-versus-host disease.
    Darmstadt GL; Donnenberg AD; Vogelsang GB; Farmer ER; Horn TD
    J Invest Dermatol; 1992 Oct; 99(4):397-402. PubMed ID: 1401996
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.